| scholarly article | Q13442814 |
| P50 | author | Christopher Eccleston | Q38327207 |
| P2093 | author name string | R Andrew Moore | |
| Andrew S C Rice | |||
| Ian Gilron | |||
| Nanna B Finnerup | |||
| Mark Wallace | |||
| Michael Rowbotham | |||
| Simon Haroutounian | |||
| Emma Fisher | |||
| David P Finn | |||
| Louisa Degenhardt | |||
| Elliot Krane | |||
| P2860 | cites work | Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement | Q21195843 |
| Amitriptyline for neuropathic pain in adults | Q24186538 | ||
| The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | Q24643876 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Influence of trial sample size on treatment effect estimates: meta-epidemiological study | Q27687577 | ||
| The knowledge system underpinning healthcare is not fit for purpose and must change | Q28262850 | ||
| Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study | Q28750315 | ||
| Meta-assessment of bias in science | Q29032830 | ||
| Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects | Q29619558 | ||
| Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses | Q33372680 | ||
| Publication bias in meta-analysis: its causes and consequences | Q33870662 | ||
| The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study | Q34058272 | ||
| Agonistic properties of cannabidiol at 5-HT1a receptors | Q34463976 | ||
| Ascertaining the size of the symptom iceberg in a UK-wide community-based survey | Q34485486 | ||
| Random error in cardiovascular meta-analyses: how common are false positive and false negative results? | Q34503295 | ||
| Gabapentin for chronic neuropathic pain in adults. | Q34557703 | ||
| Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model. | Q36071373 | ||
| The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews | Q36721160 | ||
| Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations | Q37022616 | ||
| Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies | Q37063508 | ||
| GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes | Q38006189 | ||
| GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes | Q38011509 | ||
| Small studies are more heterogeneous than large ones: a meta-meta-analysis | Q38470318 | ||
| The cannabinoid system and pain | Q38669685 | ||
| Pain and the global burden of disease | Q38670143 | ||
| Pain and mortality in older adults: The influence of pain phenotype | Q38673875 | ||
| PRISMA harms checklist: improving harms reporting in systematic reviews | Q38718135 | ||
| Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor | Q38848638 | ||
| Which chronic conditions are associated with better or poorer quality of life? | Q40746155 | ||
| Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation | Q42053693 | ||
| Managing chronic pain in children and adolescents. We need to address the embarrassing lack of data for this common problem | Q42783904 | ||
| Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability | Q44208964 | ||
| Association between analytic strategy and estimates of treatment outcomes in meta-analyses | Q45303903 | ||
| Expect analgesic failure; pursue analgesic success | Q45776628 | ||
| AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both | Q47684085 | ||
| Cannabinoids and Pain: Sites and Mechanisms of Action | Q47926319 | ||
| Professionals underestimate patients' pain: a comprehensive review | Q49919968 | ||
| Pain and mortality: mechanisms for a relationship | Q51760242 | ||
| Drug development: The treasure chest. | Q55059328 | ||
| European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management | Q56968125 | ||
| Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016 | Q58740100 | ||
| Estimating relative efficacy in acute postoperative pain: network meta-analysis is consistent with indirect comparison to placebo alone | Q60677437 | ||
| Adverse event assessment and reporting in clinical trials of cannabinoids for chronic pain: Protocol for a Systematic Review (Preprint) | Q60682873 | ||
| Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies | Q88919594 | ||
| Pharmacological interventions for chronic pain in children: an overview of systematic reviews | Q92120114 | ||
| P433 | issue | 3 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | e741 | |
| P577 | publication date | 2019-04-30 | |
| P1433 | published in | Pain reports (Baltimore, Md.) | Q27727480 |
| P1476 | title | Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials | |
| P478 | volume | 4 |
Search more.